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Abstract
Background: Access to low-cost essential generic medicines is a critical health policy goal in low-and-middle
income countries (LMICs). Guatemala is an LMIC where there is both limited availability and affordability of these
medications. However, attitudes of physicians and pharmacy staff regarding low-cost generics, especially generics
for non-communicable diseases (NCDs), have not been fully explored in Guatemala.
Methods: Semi-structured interviews with 30 pharmacy staff and 12 physicians in several highland towns in
Guatemala were conducted. Interview questions related to perceptions of low-cost generic medicines, prescription
and dispensing practices of generics in the treatment of two NCDs, diabetes and hypertension, and opinions about
the roles of pharmacy staff and physicians in selecting medicines for patients. Pharmacy staff were recruited from a
random sample of pharmacies and physicians were recruited from a convenience sample. Interview data were
analyzed using a thematic approach for qualitative data as well as basic quantitative statistics.
Results: Pharmacy staff and physicians expressed doubt as to the safety and efficacy of low-cost generic medicines
in Guatemala. The low cost of generic medicines was often perceived as proof of their inferior quality. In the case
of diabetes and hypertension, the decision to utilize a generic medicine was based on multiple factors including
the patient’s financial situation, consumer preference, and, to a large extent, physician recommendations.
Conclusions: Interventions to improve generic medication utilization in Guatemala must address the negative
perceptions of physicians and pharmacy staff toward low-cost generics. Strengthening state capacity and
transparency in the regulation and monitoring of the drug supply is a key goal of access-to-medicines advocacy
in Guatemala.
Keywords: Generic medicines, Medicine perceptions, Guatemala, Pharmacist roles, Access to medicines, Essential
medicines, Non-communicable diseases
Background
Access to essential medicines has been on the public
health agenda since the 1970s when the World Health
Organization (WHO) published the first list of essential
drugs and the Alma Ata Declaration proclaimed access
to medicines as a pillar of primary health care [1]. Pol-
icies to promote drug access initially tended to focus on
medicines for acute conditions and infectious diseases.
However, in recent years, the rapidly rising burden of
chronic non-communicable diseases (NCDs) in low-and-
middle income countries (LMICs) has led to calls for
improved access to medications for NCDs as well [2, 3].
Surveys conducted in diverse LMICs have shown that
essential medicines for NCDs tend to be unaffordable or
unavailable in both public and private sectors [4–7].
Access to low-cost essential generic medicines, and, to
an increasing degree, generics for NCDs, is thus a
critical health policy goal in LMICs. However, barriers to
generic access are complex. Demand-side constraints
may include health seekers’ negative perceptions of
generics or uncertainties regarding medicine quality [8].
On the supply side, numerous factors influence health
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providers who prescribe and dispense low-cost essential
medicines, including efficacy and safety concerns, lack
of trust between physicians and pharmacies, misaligned
incentives between patient and provider, and pharma-
ceutical promotional activity [9].
The pharmaceutical industry and generic medicines
in Guatemala
Industry analysts estimate total pharmaceutical sales in
Central America in 2014 at US$ 3.7 billion [10].
Guatemala, the most populous country in Central
America, is the region’s biggest pharmaceutical market
[10, 11]. Although approximately 70% of the US$ 800
million Guatemalan drug market by value is comprised
of imported medicines [10], with Mexico serving as the
leading source of imports by value as of 2010 [12],
there are also 70 domestic and two multinational com-
panies authorized to manufacture medicines within the
country [13]. Official documents report that 64% of all
drug purchases are made in the private sector, and the
vast majority of private health spending is out-of-
pocket [14, 15]. Prior research on access to medicines
in Guatemala, primarily focused on acute condi-
tions, has suggested that they tend to be unavailable or
unaffordable [16–19]. In general, accurate, up-to-date,
and publically available information on the pharma-
ceutical and pharmacy industries in Guatemala is
limited.
WHO defines a generic medicine as “a pharmaceutical
product, usually intended to be interchangeable with an
innovator product, that is manufactured without a li-
cense from the innovator company… [and] marketed
under a non-proprietary or approved name rather than a
proprietary or brand name [20].” In contrast, “origin-
ator” or “innovator” medicines are usually defined as the
first drugs to be authorized or patented [21]. Generics
can be branded or unbranded; a “branded generic” refers
to a generic drug sold under a trade name that is different
from the originator name. In addition, a few pharmaceut-
ical chains do exist in Guatemala which market “similares”
(non-bioequivalent copy drugs). These include branches
of the Mexican chain Farmacias Similares, which has
transformed the private-sector pharmaceutical market
in Mexico [22]. However, in Guatemala, the market
share for “similares” has remained low compared to the
generics market.
In Guatemala, multiple factors impact access to and
perceptions of generics. First, Guatemalan intellectual
property law offers relatively expansive protection for
originator pharmaceuticals relative to peer countries,
which delays the introduction of new medicines into the
generic market [23–25]. For example, in the case of the
long-acting insulin Lantus® (insulin glargine), a generic
version would still be restricted in Guatemala even after
the drug lost its patent in the United States [26]. Second,
as in many other LMICs [27], most generics sold in
Guatemala are branded generics [28]. Branded generics
in Guatemala are aggressively marketed to capture con-
sumer loyalty, thereby allowing a premium to be charged
as compared to unbranded generics [25].
An important factor impacting the perceptions of low-
cost generics in Guatemala is concern regarding generic
drug quality. Although legal frameworks mandate drug
and safety monitoring [13], domestic generic manufac-
turers operate under laws that are outdated with respect
to best manufacturing practices [13, 29]. In addition,
the limited data available suggest that there are quality
issues in the Guatemalan drug market. For example, in
the international Medicines Quality Database, whose
results have been published in aggregate form [30],
eight of the 37 medicine samples submitted from
Guatemala failed to pass a quality test [31]. A series of
dissolution studies carried out by students and faculty
at San Carlos University in Guatemala showed that, in
multiple cases, generic versions of drugs were not bio-
equivalent to originator products [29]. A 2012 Ministry
of Health report found that 5.2% of 960 pharmaceutical
quality tests did not comply with quality standards [13].
Robust and competitive generic pharmaceutical mar-
kets also require that consumers trust the public institu-
tions tasked with monitoring and protecting the drug
supply. In Guatemala, however, there is deep mistrust of
the political system [32], and there have been numerous
scandals in recent years involving collusion between gov-
ernment officials, business elites, and the pharmaceutical
and pharmacy industries. For example, in 2014 alone,
four large pharmacy chains were fined for advertising
false discounts on medicines [33], 12 international
pharmaceutical companies operating in Guatemala
were found guilty of colluding to raise the prices of
some 500 products [34], and the Guatemalan Social
Security Institute (IGSS) entered into a fraudulent
pharmaceutical procurement contract that ultimately
led to the arrest of high-profile government figures
including the director of IGSS and the president of the
Central Bank [35]. Taken together, such high-profile
scandals reinforce public skepticism of the integrity and
safety of the drug supply in Guatemala [25].
Finally, a multitude of ground-level pressures and
incentives tend to favor originator medicines over
generics. First, although physicians in Guatemala are
legally required to include generic names in prescrip-
tions, such laws are not enforced in practice. In some
cases, physicians may steer patients to their own
privately-owned pharmacies, creating a financial con-
flict of interest towards preferentially prescribing and
selling higher-cost products like originator medicines
[36]. In addition, retail pharmacies commonly advertise
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discounted or free in-house clinical consultations as a
business strategy to increase sales. Finally, while direct-
to-consumer advertising in Guatemala is not legally
permitted for any prescription medicine [13], the scope
of what is considered a prescription drug is very
narrow, and, therefore, the vast majority of drugs—in-
cluding antibiotics—can be purchased over the counter
[37]. In practice, consumers are frequently targeted in
advertisements for pharmaceutical products [38]. A
newspaper advertisement (Fig. 1) published by Fede-
farma, a trade group representing more than a dozen
well-known international pharmaceutical companies in
Central America, illustrates this dynamic well. Fedefarma
promotes originator brands to prospective consumers [39]
and clinicians [40] by emphasizing themes of quality,
safety, and bioequivalence.
Against this background, it remains unclear how the
attitudes toward generics of pharmaceutical gatekee-
pers—prescribing physicians and retail pharmacy
staff—impact the access and use of these medicines.
One recent study utilized an online survey to demon-
strate that many physicians perceived generics to be of
lower quality than originator brands, while, at the same
time, their prescribing practices were influenced by the
affordability of such medicines for patients [41]. How-
ever, this study did not examine how other factors such
as how interaction with pharmaceutical representatives
may also impact perceptions. Additionally, no studies
have examined the perceptions of pharmacy staff to-
wards generic medications or how pharmaceutical gate-
keepers view generic NCD drugs.
These are important gaps in knowledge since medi-
cines in Guatemala are largely purchased as an out-of-
pocket household expense at pharmacies [14, 15]. Even
in the public sector, medicines are often out of stock,
and, thus, public providers may write prescriptions for
patients to purchase medicines privately. Many health
seekers eschew clinical providers altogether and directly
seek care at pharmacies [37, 42–44]. In this setting,
pharmacy staff may theoretically steer patients away
from generics or “upsell” originator products.
To examine these issues, we undertook a mixed-
methods study (1) to explore physician and retail phar-
macy staff ’s perceptions regarding generic and medicines
and (2) to investigate how these perceptions influence
on-the-ground prescribing and dispensing decisions of
generic medicines including drugs for NCDs.
Methods
Institutional context and ethics
This study was facilitated by Wuqu’ Kawoq | Maya Health
Alliance, a non-governmental organization (NGO) working
to provide health services, including services for NCDs, in
rural indigenous Maya communities in Guatemala. This
study was reviewed and approved by the Institutional
Review Boards of Wuqu’ Kawoq | Maya Health Alliance
and Partners Healthcare, Boston. All participants pro-
vided verbal informed consent.
Overview of methods
The study consisted of semi-structured interviews con-
ducted with 42 physicians and pharmacy staff in three
Fig. 1 Advertisement in Guatemala promoting originator medicines over generic medicines. In English the text reads: I have diabetes. If my
medicine fails, I could suffer a diabetic coma. I don’t play around; I only use the real thing. Trusted brands [“originator medicines”] have studies that
back up their quality, efficacy, and safety. Respect the medical prescription. Ask your doctor or your pharmacist for originator medicines. Image used
with permission of Health Action International
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locations in central Guatemala in the province of Chi-
maltenango: San Juan Comalapa (population 42,200),
Tecpán (population 81,100), and the provincial capital
Chimaltenango (114,400). These towns were selected as
study sites because they represented large concentrations
of patients with NCDs for the sponsoring NGO.
Sample recruitment
Thirty retail pharmacy staff were recruited to the study
through random sampling of pharmacies in San Juan
Comalapa, Tecpán, and Chimaltenango. “Pharmacy staff”
was defined broadly to include any pharmacy worker
who dispensed medications to clients, regardless of level
of training or professional certification. People in San
Juan Comalapa and Tecpán commonly purchase medi-
cines both locally and in the city of Chimaltenango, due
to its central location along the major highway leading
to both towns. In each of these three towns, the research
team created a comprehensive map of all pharmacies
and classified each pharmacy in one of five categories:
(1) national pharmacy franchise, (2) discount local
pharmacy, (3) non-discount local pharmacy, (4) hybrid
clinic-pharmacy; or (5) government-subsidized pharmacy
(through the national Program for Medication Accessi-
bility [PROAM]). In each town, three pharmacies were
randomly selected within each category. In San Juan
Comalapa and Tecpán, fewer than three pharmacies
were present for some categories; in these cases, all
pharmacies within a town’s category were selected. In
total, across the three locations, interviewees were re-
cruited from 30 distinct pharmacies whose classifications
are reported in Table 1A.
Twelve physicians were recruited to the study from
San Juan Comalapa, Tecpán, and Chimaltenango. Con-
venience sampling was used. The research team identi-
fied and contacted physicians in all three locations
through referrals from health professionals working in
San Juan Comalapa and Tecpán. In Chimaltenango, the
research team performed site visits to clinics where the
sponsoring NGO’s patients commonly reported accessing
care. Across the three locations, physician participants
were recruited from 12 distinct practice environments as
reported in Table 1B.
Data collection
Semi-structured interviews lasting 20–45 min were con-
ducted with pharmacy staff and physicians in their place
of work. All interviews were conducted in Spanish.
Interviews with pharmacy staff focused on training,
perceptions of generic medicines, prescription practices
regarding medicines for diabetes and hypertension,
advice given to clients with diabetes and hypertension,
and opinions about the roles of pharmacy staff and phy-
sicians in care delivery. Interviews with physicians
focused on perceptions of generic medicines including
generics for diabetes and hypertension, prescribing prac-
tices, and opinions about the roles of pharmacy staff and
physicians in care delivery. We opted not to define “ori-
ginator medicines,” “branded generics,” or “unbranded
generics” to research participants given that such defini-
tions can be technically complex and that these terms
are not used regularly in clinics and pharmacies in
Guatemala. As we were most interested in the percep-
tions and utilization of low-cost generics, which in
Guatemala generally refer to unbranded generics, we
used the term “generic” in research questions in contrast
to “commercial brands,” as these are the terms most
commonly used and understood by participants in this
setting. Detailed notes were taken during and after each
interview, and these serve as the basis for analysis.
Data analysis
Qualitative data from interviews was analyzed using an
inductive approach, allowing dominant themes to
emerge from interview notes. Lists of responses to each
open-ended question were compiled in matrices orga-
nized by participant type. Responses were then coded
into thematic categories by one researcher [IM]. Other
team members collectively reviewed and arrived at con-
sensus about the application of codes. Finally, as it was
hypothesized that pharmacy staff and physicians’
Table 1 Characteristics of pharmacies and physicians surveyed
A. Pharmacy characteristics (n = 30) Number (percent)
Town of pharmacy surveyed
San Juan Comalapa 8 (27%)
Tecpán 8 (27%)
Chimaltenango 14 (47%)
Category of pharmacy (n = 30)
National pharmacy franchise 6 (20%)
Discount local pharmacy 7 (23%)
Non-discount local pharmacy 8 (27%)
Hybrid clinic-pharmacy 5 (17%)
Government-subsidized pharmacy 4 (13%)
B. Physician characteristics (n = 12)
Town of physician clinic surveyed
San Juan Comalapa 5 (42%)
Tecpán 5 (42%)
Chimaltenango 2 (17%)
Category of practice environment
Public 3 (25%)
Private 6 (50%)
Private and public 2 (17%)
NGO 1 (8%)
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perspectives might differ across interview topics, coded
responses in the matrices were compared across par-
ticipant type. Quantitative data derived from interviews
were first entered into a spreadsheet and then imported
into Stata (StataCorp; College Station, TX) for analysis.
In addition to descriptive statistics, Fisher’s exact test
was used to compare categorical responses between
physicians and pharmacy staff.
Results
Demographics and education
Thirty pharmacy staff and 12 physicians were inter-
viewed. Demographic characteristics of participants are
summarized here and in Table 2. Of the 12 physicians
sampled, eight were general practitioners who had
completed medical school but no further training, three
had completed post-graduate residency programs, and
one had received a master’s degree in epidemiology.
Ten participants attended medical school in Guatemala
and two in Cuba.
Among pharmacy staff, the level of formal education
prior to entering the pharmacy business varied widely
but was typically low, with only two of 30 respondents
having received any formal post-high school education.
When pharmacy staff were queried as to why they had
entered the retail pharmacy field, they expressed a
diverse range of motivations, including professional
interest in the field, desire to help people, previous
work in health care (such as nursing or social work),
or economic necessity. Participants often cited social
connections as drawing them into the profession, such
as having a neighbor, family member, or spouse who
worked in a pharmacy practice.
Level of pharmacy-specific training or certification also
varied widely. Half of participants had received no
pharmacy-specific training of any kind. Among those
who did report receiving such training, the quality and
nature of the training was heterogeneous. Some reported
training that consisted of “reading pharmacy books”
while others had engaged in on-the-job apprenticeships
within pharmacies or clinics. Some participants referred
to prior experience with medications, gained from
working in a different health care environment, such as
a nursing home or clinic. Among those who self-
reported any kind of pharmacy-specific training, the
duration of that training was 5.4 ± 8.5 months. Only
seven (23%) self-reported earning a license to practice
in a pharmacy setting.
General perceptions of generic cost, safety, and efficacy
Pharmacy staff and physicians’ perceptions of the safety
and efficacy of generic medicines are summarized in
Table 3. In general, physicians were more likely than
pharmacy staff to perceive generic medications to be
less safe or less effective. However, these differences in
perceptions were not statistically significant, likely due
to our small sample size.
Among pharmacy staff, 41% believed that generics
were not as safe as drugs with commercial brand names,
whereas 33% believed that they were not as effective.
When asked to elaborate on their perceptions of generic
drugs, nine pharmacy staff cited “inferior manufacturing
ingredients” or “low quality.” They also cited specific ex-
amples of clients who had experienced different thera-
peutic responses, such as changes in blood pressure or
glycemic control, when switching between branded and
generic medications as evidence of generics’ inferiority.
Eight participants reasoned that generic medicines’ low
cost was in itself proof of low quality, explaining that
because they are “too economical” or “cheap,” generic
medicines could not possibly have equal effectiveness.
Five participants were concerned by reports they had
read in the popular press or trade journals about the
heterogeneous quality of various companies’ manufac-
turing processes. Nine pharmacy staff reported that the
distinction between generics and “branded medications”
was the branding process itself; “the only difference is
the brand because the quality is the same,” as one
respondent remarked. One participant distinguished be-
tween generic medicines made by trusted manufacturers
Table 2 Demographic characteristics of participants
Pharmacy staff Physicians
Participants (n) 30 12
Formal Education level, n (%) Elementary school: 2 (7)
Middle school: 9 (30)
High school: 17 (57)
Post-high school: 2 (7)
Medical school: 8 (67)
Residency: 3 (25)
Master’s degree: 1 (8)
Pharmacy Specific Training
No training, n (%) 15 (50%) N/A
Mean duration of training, months ± SD 5.4 ± 8.5 N/A
Pharmacy certification, n (%) 7 (23%) N/A
Mean Work experience, years ± SD 7.3 ± 5.7 13.5 ± 10.4
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and “generic generics,” which the participant deemed to
be less reputable.
Pharmacy staff who worked at a national pharmacy
franchise or a for-profit hybrid clinic-pharmacy were
more likely to view generics as less safe than those who
worked at community or public pharmacies (26% vs.
70%, p = 0.046). A similar trend effect was observed for
the perception of efficacy but was not statistically signifi-
cant (21% vs. 55%, p = 0.11).
Among physicians, 55% believed that low-cost generics
were not as safe as “branded drugs,” and 55% also stated
that they were not as effective. Nine participants
expressed at least some reservations about the use of
generic medications, with typical comments including
that “they are not adequately manufactured,” “they don’t
have good quality control,” and “they don’t offer the
same results to the patient.” Physicians also acknowl-
edged the heterogeneity of generic drug quality, which
was perceived to be dependent on the reliability of the
manufacturer. Like pharmacy staff, some physicians
reasoned that the low cost of generic drugs was itself
indicative of inadequate quality.
When asked about the differences between generic
and non-generic drugs, physicians cited prestige in
addition to safety and efficacy concerns. One physician
explained that patients feel “proud” to be able to pay
for expensive drugs. Three physicians described pre-
scribing low-cost generic medicines and subsequently
switching to a more expensive drug with a brand name
when the generic version was perceived to be ineffect-
ive. One participant explained that patients with previ-
ous exposure to high-cost drugs with brand names
would not respond as well when “downgraded” to a
low-cost generic version.
Interactions with pharmaceutical company
representatives
Pharmacy staff and physicians were asked about their in-
teractions with pharmaceutical representatives. Twenty-
six of 30 pharmacy staff reported visits from pharma-
ceutical representatives. Seven said that they had re-
ceived incentives from representatives in the form of
drug samples, price discounts, pens, notebooks, calen-
dars, prizes, and informal presentations. Nineteen phar-
macy staff cited pharmaceutical representatives among
the resources they used to learn about the latest
pharmaceutical products.
Responses were similar among physician participants.
All but two of the 12 physicians interviewed said that
pharmaceutical sales representatives regularly visited
them. Of these 10, four reported receiving incentives
from pharmaceutical representatives, including drug
samples, electronic office equipment, payment of regis-
tration for conferences, calendars, and prescription pads.
When asked how they stayed up-to-date on current
medical literature, eight physicians cited information
provided by pharmaceutical companies and their repre-
sentatives among other resources. No statistically signifi-
cant relationship was observed between interactions with
pharmaceutical representatives or the receipt of gifts from
representatives with perceptions of safety or efficacy of ge-
nerics for either pharmacy staff or physicians.
Generic drug utilization for diabetes and hypertension
In the case of diabetes and hypertension, prescribing prac-
tices of physicians and dispensing practices of pharmacy
staff varied widely and were influenced in part by percep-
tions regarding the efficacy and safety of low-cost generics.
When pharmacy staff were asked how they decide whether
to dispense low-cost generic medicine for a patient with a
chronic disease, they were in general agreement that it
depended on patients’ financial resources and the severity
of the condition, with wealthier and sicker patients less
likely to be dispensed generics. Many pharmacy staff also
emphasized that the decision to use a generic was ultim-
ately up to the patient. As one participant commented,
regarding chronic disease medicines, “I tell them, do you
want the expensive one or cheap one? Some people die
because they don’t want to buy a generic medicine.” One
pharmacy worker added that, in the case of chronic dis-
eases, it was the role of pharmacies “to educate people, so
they don’t get tricked by brand-name marketing.”
Three physicians cited the patient’s clinical history and
prior drug regimens as important factors in deciding
what to prescribe. For instance, one participant explained
that a more severe clinical presentation or a “very chronic
disease” would call for a non-generic medicine, although
starting with a generic version and switching if it were in-
effective might be acceptable practice. Several participants
expressed that concerns regarding the effectiveness and
safety of generic medicines influenced their clinical
practice. One physician commenting on chronic disease
medicines stated, “To prescribe generics is to play with
the life of the patient.”
Table 3 Perceptions of safety and efficacy by pharmacy staff and physicians
Pharmacy staff (n = 30) Physicians (n = 12) P-value
Generics are not as safe as branded drugs 12 (41%)a 6 (55%)a 0.50b
Generics are not as effective as branded drugs 10 (33%) 6 (55%)a 0.29b
aA few respondents answered “do not know” and their answers are excluded from this calculation
bFisher’s exact test
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Roles of physicians and pharmacy staff in providing
chronic disease care
The majority of pharmacy staff (87%) stated that a pre-
scribing physician should determine the medicines for
diabetes or hypertension. Similarly, most pharmacy staff
reported that it is more common for patients with dia-
betes or hypertension to arrive at the pharmacy with a
physician prescription in hand than to ask for a treat-
ment recommendation at the pharmacy. Only 27% of
pharmacy staff reported dispensing a medication other
than the prescribed medication to a patient with diabetes
or hypertension.
In addition to dispensing medications, most pharmacy
staff described providing additional medical counseling
to patients with diabetes and hypertension. Eighty per-
cent of participants reported offering advice to patients
with diabetes and 63% reported giving advice to patients
with hypertension. Pharmacy worker advice for man-
aging diabetes included exercise and decreasing the
intake of sugar, sugary foods, and fats. In addition to
pharmaceuticals, pharmacy staff participants also rec-
ommended vitamins, herbs, and electrolyte solutions
specifically marketed for patients with diabetes. When
providing advice for hypertension, pharmacy staff simi-
larly emphasized increasing physical activity, making
dietary changes, and improving psychological well-being.
Participants also suggested natural remedies including
chamomile tea and garlic with honey.
When physicians were asked about the overall role of
pharmacy staff in patient care, several key themes
emerged. In particular, interviewed physicians expressed
concern about the lack of formal training among phar-
macy staff as well as their competing desire to broker
the sale of medicines. Physicians frequently stated that
the role of pharmacists should be to dispense the medi-
cines as prescribed by the physician without substitu-
tions and to provide education about medicines.
Discussion
Through semi-structured interviews with physicians and
pharmacy staff in Guatemala, this study explored per-
ceptions of low-cost generic drugs in clinical practice
and how these perceptions of pharmaceutical gate-
keepers impact prescribing and dispensing decisions.
Our results offer several insights regarding use and ac-
cess to low-cost generic medicines, including generics
for NCDs, that merit further discussion.
First, both physicians and pharmacy staff expressed
doubt as to the safety and efficacy of low-cost generic
medicines in Guatemala, in part due to concerns about
low manufacturing standards and quality control, which
influenced their daily prescribing and dispensing prac-
tices. Our results echo studies from other LMICs where
physicians and pharmacy staff have expressed mixed or
negative perceptions regarding the safety and efficacy of
generics [45–48]. One review examining physician per-
spectives of generic drugs found that doctors in LMICs
tend to have less positive views of generics compared to
doctors in high-income countries, who had more posi-
tive perceptions [49]. Another review of both physician
and pharmacist perceptions of generics similarly distin-
guished between the high trust of generics in mature
health systems and the low trust in generic quality,
manufacturing, and bioequivalence in less mature health
systems [50].
Second, we found that both physicians and pharmacy
staff in Guatemala utilize cost as a heuristic for the qual-
ity of the medicines they prescribe and dispense. The
use of cost as proxy for the quality of pharmaceutical
products has been previously reported in Guatemala and
in other LMICs. Indeed, there is some evidence that
price does at times serve as an indicator for quality; a
recent study of essential medicines from private pharma-
cies in 17 LMICs found that failing drugs were on
average priced 13.6–18.7% lower than non-failing drugs
[51]. Some commentators writing about Guatemala from
the field of anthropology have argued that high-priced
health care products serve not only to emphasize per-
ceptions of quality but also to appeal to a desire for so-
cial status and upward mobility [52, 53]. In the present
study, this viewpoint is buttressed by the response of
some participants, such as the physician who remarked
that some patients “feel proud” to pay for expensive
drugs. Furthermore, others have shown that the com-
mercial aspects of medications, such as pricing, may
influence the placebo effect [54], and it is therefore
reasonable to speculate that cost may indeed affect
clinical outcomes independent of a difference in intrin-
sic efficacy between products.
Third, our results show that physicians, pharmacy
staff, and consumers all play a role in determining
whether a low-cost generic is ultimately utilized in
practice for NCDs. The incentives of each of these ac-
tors and the forces that influence them are complex,
yet policy implications emerge. We report that phar-
macy staff generally, though not always, defer to phys-
ician prescriptions, which points to a need to enforce
laws requiring generic name in prescriptions and other-
wise improve communication between prescribers and
dispensers. We also found that pharmaceutical repre-
sentatives frequently visit physicians and pharmacy staff
in Guatemala and provide education about new phar-
maceuticals. The ubiquity of these visits and the use of
gifts and prizes call attention to a need for a well-
articulated government policy regarding interactions
between pharmaceutical representatives and providers.
Although our study did not show a statistically signifi-
cant relationship between perceptions of generics and
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interactions with pharmaceutical representatives, the
small sample size and very low numbers of recruited
participants who did not interact with pharmaceutical
representatives means that our study was significantly
underpowered to detect a difference.
Fourth, our results show that pharmacy staff generally
have low levels of education and training, yet they play
an important role in educating patients about medicines
and chronic diseases like diabetes and hypertension.
Although this study was not designed to evaluate
pharmacy worker decision-making, there is a significant
literature showing that pharmacy staff in many LMICs
[55, 56], including Guatemala [57, 58], do not deliver
treatment advice in accordance with commonly-
accepted medical standards. However, in this study,
pharmacy staff reported that physicians should be the
gatekeepers who determine diabetes and hypertension
medicines for patients, that it was more common for
patients with diabetes and hypertension to present with
physician prescriptions than to ask for advice at phar-
macies, and that they did not frequently switch out
physician prescriptions. These finding are at odds with
the existing literature in the region, which, focusing
largely on medications for acute illnesses, finds that
most dispensing occurs without the involvement of a
prescribing physician [37, 43, 44, 57, 59].
Although these results are subject to methodological
bias, they are surprising and unexpected, and they re-
quire confirmation and exploration in a larger study.
One possibility is that the culture of pharmaceutical dis-
pensing is slowly changing in Guatemala, with a move
towards more formal reliance on physician prescriptions.
Along these lines, it is worth noting that some key stud-
ies of pharmaceutical dispensing in the region are now
more than 10 years old [57, 58], and so it is likely time
to revisit the issue, including reanalyzing dispensing
practices for antibiotics and other acute illness medica-
tions. Alternatively, it may be that informally-trained
pharmacy workers are simply less comfortably dispens-
ing medications for chronic diseases. This could be
because of relative limitations in their knowledge about
these medications, exacerbated by the rapid diversifica-
tion of and growth in products in the chronic illnesses
market, which are rapidly outpacing the relatively more
stable market for antimicrobials, analgesics, and the like.
We also hypothesize that the higher cost of medications
for chronic illness is a contributory factor. Given the
higher financial stakes, it may be that clients or dispens-
ing practitioners increasingly prefer to formalize transac-
tions with the aid of a written physician prescription.
From a broader perspective, previous literature out-
lines four main categories of barriers to the implementa-
tion of pro-generic policies in LMICs: (1) legal barriers;
(2) management and institutional barriers; (3) behavior,
perception, and knowledge barriers; and (4) financial
barriers [9]. This study principally addresses the third
category—in particular, the perceptions of physicians
and pharmacy staff and how these perceptions influence
clinical behavior. Our results indicate that improving at-
titudes toward low-cost generics is an important goal. At
the same time, as we have detailed in the introduction to
this article, there is compelling evidence in Guatemala to
support the belief that the safety and efficacy of the drug
supply cannot be guaranteed. Indeed, the issue of sub-
standard and counterfeit medicines is a concern in many
LMICs [30, 60–63]. In the Guatemalan setting, where
regulatory information is limited and drug quality is
uncertain, it is thus not surprising that the high price of
trusted pharmaceutical brands is therefore used as a
surrogate marker for quality.
Taken in context, our results also underline the fact
that interventions to improve the perception of low-cost
generics and increase their utilization by physicians and
pharmacy staff would be insufficient without commen-
surate efforts to strengthen the regulation and transpar-
ency of the drug supply. Unfortunately, in Guatemala’s
current political climate, it is difficult to imagine any in-
creased state capacity for regulating or ensuring generic
drug supplies in the near future. However, we do see
two potential promising avenues. First, in recent years,
the Guatemalan judicial system, reinforced by backing
from the United Nations’ International Commission
against Impunity in Guatemala (CICIG), has made con-
siderable inroads in fighting high-level government cor-
ruption, including in the health care sector [64]. We
hope that CICIG’s activities will reduce high-profile drug
procurement scandals, such as those we mentioned in
this paper’s Introduction, and may help to increase pub-
lic confidence in generic medications. Second, we can
see a role for voluntary self-organization and self-
regulation by generics manufacturers. Commitments to
increased transparency and accountability, for example
through reporting on compliance with international
manufacturing standards and bioequivalence testing,
could go a long way both in improving the quality of the
generics drug supply and confronting the allegations of
inferiority in both the popular press and the promo-
tional materials of originator brands. Such commit-
ments would no doubt come at increased production
costs, but these could potentially be offset as public
opinion improved and sales increased.
Study limitations and future directions
This study has several methodological limitations that
limit the generalizability of our findings. First, the
sample size of physicians and pharmacy staff was small
with limited power to detect some important differences,
especially regarding interaction with pharmaceutical
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representatives. Physicians were recruited based on a
convenience sampling strategy that could have intro-
duced bias. Second, geographically, participants were
concentrated in one particular region of Guatemala, and
their opinions may not reflect the views of physicians
and pharmacy staff throughout Guatemala. In particu-
larly, the study did not sample participants in Guatemala
City, which is the country’s dominant urban area from
both a population and economic perspective, nor did
we consider the self-reported ethnicity of providers or
pharmacy staff themselves in creating our sample. Add-
itionally, as we did not define “originator medicines,”
“branded generics,” and “unbranded generics” to re-
search participants, we are unable to make firm distinc-
tions among the perceptions of drugs in each of these
categories. The “branded generic conundrum” has
emerged as a primary challenge of the generic medicine
policy agenda [63]. Further inquiry into the perception,
price, and utilization of branded generics in Guatemala
in relation to originator products and unbranded
generics is an important future research goal for our
team. We also intend to explore in greater detail the
unexpected findings about reluctance to dispense medi-
cations for chronic illness without a prescription, and
to investigate more closely the relationship between
prescribing practices and interactions with pharmaceutical
representatives. In this regard, the frequency of interaction
with pharmaceutical representatives we measure in this
study will permit sample size calculations for an ad-
equately powered subsequent study.
Conclusion
This study demonstrates that physician and pharmacy
staff ’s perceptions of low-cost generics influence the
utilization of these medicines in clinical practice, es-
pecially in relation to the treatment of NCDs like dia-
betes and hypertension. Interventions to improve the
perception of generics and increase their utilization
by physicians and pharmacy staff are critical. At the
same time, additional research on changing dispensing
practices of medications for both acute and chronic
illnesses is needed, as is further investigation of the
impact of interactions with pharmaceutical representa-
tives on prescribing and dispensing practices. Although
short-term prospects for increasing state capacity for
regulation and monitoring of the drug supply are lim-
ited, we anticipate that the emergent anti-impunity
movement in Guatemala will increase public trust in
generic medications by reducing high-profile scandals
over drug procurement schemes. Furthermore, we sug-
gest that the generics industry, through self-regulation
and self-organizing, could improve the quality of the
generics market while simultaneously increasing their
market share.
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